At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 158 enrolled
Drug / intervention
CS+SG +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee
In Brief
A Phase 3 clinical trial evaluating CS+SG and Placebo for Knee Osteoarthritis. Completed, enrolled 158 participants across 1 site.
Detailed Summary
The main objective is to assess the efficacy of a new formulation containing chondroitin sulfate and glucosamine sulfate (CS+GS) compared with placebo in patients with primary osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis
CountriesSpain
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJul 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedJul 9, 2013
Enrollment StartJun 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.0 years ago
Interventions
CS+SGdrug
Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
Placebodrug
Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.